CATALIST-LISTED medical technology firm Biolidics on Tuesday morning requested an immediate trading halt, pending a revised press statement with clarifications on the reimbursement for cancer laboratory-developed tests (LDTs) in China.

THE following companies saw new developments that may affect trading of their shares on Tuesday:

SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs) in the field of circulating tumour cells (CTCs) using Biolidics' ClearCell FX1 System and CTChip FR1 b...

SINGAPORE (Apr 1): Phillip Securities is initiating coverage of Clearbridge Health (CBH) with a “buy”. Phillip likes CBH’s business strategy of acquiring asset-light and fast-growing healthcare segments. After the acquisition, the group will then grow the businesses through expansion in capac...

SINGAPORE (Apr 1): Phillip Securities is initiating coverage of Clearbridge Health (CBH) with a “buy”. Phillip likes CBH’s business strategy of acquiring asset-light and fast-growing healthcare segments. After the acquisition, the group will then grow the businesses through expansion in capac...

SINGAPORE (Mar 27): CGS-CIMB is starting coverage of biotech firm Biolidics at “add” given it is the developer of game-changing liquid biopsy technology for detecting cancer. CGS-CIMB says liquid biopsy offers several advantages over tissue biopsy, including greater availability, higher quality...

SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells. See: Biolidics selling 27.5 mil n...